Highlights
FUTURA MEDICAL Annual Report 07 01
Substantial progress across the Company as it moves closer to regulatory
approval of its first condom product, CSD500
CSD500 - Statistically significant clinical trial results reinforcing the product's
commercial potential
MED2002 - Global development, marketing and licensing agreement signed
with SSL International plc for the Company's topically applied gel for erectile
dysfunction
TPR100 - Exclusivity agreement signed with GlaxoSmithKline Consumer
Healthcare for the evaluation of Futura's topical formulations for pain relief and
the negotiation of global distribution rights
PET500 - Exciting new application of our DermaSys® technology for the treatment
of premature ejaculation and Phase I study to commence shortly
South East England Development Agency ("SEEDA") grant awarded of up to
£200,000
Funding raised of £1.00 million with further £1.00 million equity funding
facility arranged
Net loss of £2.25 million (2006: net loss of £1.78 million)
Cash of £2.64 million at 31 December 2007 (2006: £3.78 million including
medium term deposits)
